BUSINESS

• FDA Approves 2-Month Long-Acting Abilify: Otsuka/Lundbeck
  May 1, 2023

• Takeda Files TAK-662 for Congenital Protein C Deficiency in Japan
  May 1, 2023

• Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
  April 28, 2023

• Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
  April 28, 2023

• Chugai’s Q1 Profit Drops by Half in Pullback from Alexion Settlement Gain
  April 28, 2023

• Astellas to Promote HR Chief Katsuyoshi Sugita to EVP
  April 28, 2023

• Taiho’s Futibatinib Nabs EU Panel Backing for Bile Duct Cancer
  April 28, 2023

• Chugai Seeks Vabysmo Label Expansion for RVO
  April 28, 2023

• 374 Chugai Employees Apply for Voluntary Redundancy Program
  April 28, 2023

• Global PIII Launched for Novel β-Lactamase Inhibitor Nacubactam: Meiji
  April 27, 2023

• Pfizer Japan Files Combo Antibiotic Containing β-Lactamase Inhibitor
  April 27, 2023

• Stelues Data in Japanese to Be Gathered via Normal Pharmacovigilance Activities: Pfizer
  April 27, 2023

• Pfizer Japan Files Genotropin for Prader-Willi Syndrome
  April 26, 2023

• HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
  April 26, 2023

• Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
  April 26, 2023

• Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
  April 25, 2023

• Santen to Forge Ahead with Structure Reform, Revenue Revamp to Upscale Growth
  April 25, 2023

• Actemra Approved in Taiwan for Hospitalized COVID-19 Patients: Chugai
  April 25, 2023

• Takeda Installs Chief Tech Officer Role as It Revs Up Digital Drive: CEO
  April 24, 2023

• Mitsubishi Sent Letter Agreeing to Call Off Muse Cell License Deal: Researchers
  April 24, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 147
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• …
• Next ›
• 最終 »